What is Zacks Research’s Forecast for Perrigo Q1 Earnings?

Perrigo Company plc (NYSE:PRGO) – Equities researchers at Zacks Research lowered their Q1 2027 EPS estimates for Perrigo in a research note issued to investors on Monday, March 23rd. Zacks Research analyst Team now forecasts that the company will earn $0.68 per share for the quarter, down from their prior estimate of $0.69. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Perrigo’s current full-year earnings is $2.56 per share. Zacks Research also issued estimates for Perrigo’s Q2 2027 earnings at $0.54 EPS, FY2027 earnings at $2.51 EPS and FY2028 earnings at $2.57 EPS.

Other analysts have also recently issued research reports about the company. Canaccord Genuity Group reduced their price target on Perrigo from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Friday, February 27th. Jefferies Financial Group reissued a “hold” rating on shares of Perrigo in a report on Thursday, February 26th. JPMorgan Chase & Co. reduced their target price on Perrigo from $20.00 to $18.00 and set a “neutral” rating for the company in a report on Monday, December 15th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Perrigo in a research report on Monday, December 22nd. Finally, Argus upgraded Perrigo to a “hold” rating in a report on Wednesday, January 14th. One equities research analyst has rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Reduce” and a consensus price target of $19.33.

Perrigo Trading Up 3.5%

Shares of NYSE:PRGO opened at $9.58 on Tuesday. The company has a current ratio of 2.76, a quick ratio of 1.63 and a debt-to-equity ratio of 1.23. The stock has a market capitalization of $1.32 billion, a PE ratio of -0.93, a P/E/G ratio of 1.09 and a beta of 0.41. Perrigo has a 1 year low of $9.23 and a 1 year high of $28.43. The firm has a fifty day moving average price of $13.18 and a 200 day moving average price of $15.91.

Perrigo (NYSE:PRGO) last posted its earnings results on Thursday, February 26th. The company reported $0.77 EPS for the quarter, missing the consensus estimate of $0.80 by ($0.03). The business had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.09 billion. Perrigo had a positive return on equity of 9.41% and a negative net margin of 33.51%.The business’s revenue was down 2.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.93 earnings per share. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS.

Perrigo Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 24th. Investors of record on Monday, March 2nd will be paid a dividend of $0.29 per share. The ex-dividend date is Monday, March 2nd. This represents a $1.16 annualized dividend and a yield of 12.1%. Perrigo’s dividend payout ratio is presently -11.28%.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of PRGO. EverSource Wealth Advisors LLC grew its position in Perrigo by 116.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock worth $26,000 after purchasing an additional 1,014 shares during the last quarter. Geneos Wealth Management Inc. raised its stake in shares of Perrigo by 439.1% in the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after purchasing an additional 786 shares in the last quarter. UMB Bank n.a. lifted its position in Perrigo by 161.5% in the fourth quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock worth $27,000 after purchasing an additional 1,213 shares during the period. Meeder Asset Management Inc. acquired a new stake in Perrigo during the fourth quarter worth $28,000. Finally, CWM LLC increased its holdings in Perrigo by 230.0% in the 4th quarter. CWM LLC now owns 2,191 shares of the company’s stock valued at $31,000 after buying an additional 1,527 shares during the period. 95.91% of the stock is currently owned by institutional investors and hedge funds.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.